LCM
LXEO icon

Laurion Capital Management’s Lexeo Therapeutics LXEO Stock Holding History

Laurion Capital Management’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-260,228
Closed -$903K – 463
2025
Q1 		$903K Hold
260,228
– – 0.02% 179
2024
Q4 		$1.71M Hold
260,228
– – 0.03% 188
2024
Q3 		$2.35M Sell
260,228
-193,354
-43% -$2.31M 0.03% 150
2024
Q2 		$7.28M Sell
453,582
-600
-0.1% -$8.71K 0.09% 134
2024
Q1 		$7.12M Buy
454,182
+198,881
+78% +$3.11M 0.06% 224
2023
Q4 		$3.43M Buy
+255,301
New +$3.17M 0.03% 264

Other funds holding LXEO

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Laurion Capital Management's LXEO Position: Q2 2025 in Review

Laurion Capital Management sold out of Lexeo Therapeutics (LXEO) in Q2 2025, closing a stake of 260,228 shares — an estimated $903K sold.

Laurion Capital Management first reported a position in LXEO in Q4 2023 and held it in 6 quarters. The position peaked at $7.28M in Q2 2024. 90 funds tracked by Wall St. Rank hold LXEO as of Q2 2025.

  • Laurion Capital Management reported no remaining Lexeo Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Laurion Capital Management sold 260,228 Lexeo Therapeutics shares in Q2 2025, an estimated $903K.
  • Laurion Capital Management first reported a position in Lexeo Therapeutics in Q4 2023 and held it in 6 quarters.
  • Laurion Capital Management's Lexeo Therapeutics position peaked at $7.28M in Q2 2024.
  • 90 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2025.

Based on Laurion Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.